Importance of Endocrine Treatment Adherence and Persistence in Breast Cancer Survivorship: a Systematic Review

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2023 Jul 4

PMID 37403065

Authors

Finn Magnus Eliassen

Vibeke Blafjelldal

Thomas Helland

Cathrine Fonnesbech Hjorth

Kari Holland

Lise Lode

Bjorn-Erik Bertelsen

Emiel A M Janssen

Gunnar Mellgren

Jan Terje Kvaloy

Havard Soiland

Tone Hoel Lende

Affiliations

Soon will be listed here.

Abstract

Purpose: Adjuvant endocrine treatment is essential for treating luminal subtypes of breast cancer, which constitute 75% of all breast malignancies. However, the detrimental side effects of treatment make it difficult for many patients to complete the guideline-required treatment. Such non-adherence may jeopardize the lifesaving ability of anti-estrogen therapy. In this systematic review, we aimed to assess the consequences of non-adherence and non-persistence from available studies meeting strict statistical and clinical criteria.

Methods: A systematic literature search was performed using several databases, yielding identification of 2,026 studies. After strict selection, 14 studies were eligible for systematic review. The review included studies that examined endocrine treatment non-adherence (patients not taking treatment as prescribed) or non-persistence (patients stopping treatment prematurely), in terms of the effects on event-free survival or overall survival among women with non-metastatic breast cancer.

Results: We identified 10 studies measuring the effects of endocrine treatment non-adherence and non-persistence on event-free survival. Of these studies, seven showed significantly poorer survival for the non-adherent or non-persistent patient groups, with hazard ratios (HRs) ranging from 1.39 (95% CI, 1.07 to 1.53) to 2.44 (95% CI, 1.89 to 3.14). We identified nine studies measuring the effects of endocrine treatment non-adherence and non-persistence on overall survival. Of these studies, seven demonstrated significantly reduced overall survival in the groups with non-adherence and non-persistence, with HRs ranging from 1.26 (95% CI, 1.11 to 1.43) to 2.18 (95% CI, 1.99 to 2.39).

Conclusion: The present systematic review demonstrates that non-adherence and non-persistence to endocrine treatment negatively affect event-free and overall survival. Improved follow-up, with focus on adherence and persistence, is vital for improving health outcomes among patients with non-metastatic breast cancer.

Citing Articles

The impact of interprofessional collaboration between pharmacists and community health workers on medication adherence: a systematic review.

Bandiera C, Ng R, Mistry S, Harris E, Harris M, Aslani P Int J Equity Health. 2025; 24(1):58.

PMID: 40022158 PMC: 11869407. DOI: 10.1186/s12939-025-02415-4.

Are breast cancer patients with low distress at diagnosis at risk of psychological symptoms later in their disease trajectory? Considerations for when to screen for distress.

Langballe R, Mertz B, Kroman N, Maltesen T, Rosthoj S, Bidstrup P Acta Oncol. 2025; 64:105-113.

PMID: 39863933 PMC: 11788679. DOI: 10.2340/1651-226X.2025.42367.

Feasibility and Acceptability of Integrating Acupuncture for Management of Multiple Symptoms in Medically Underserved Breast Cancer Survivors.

Li H, Doorenbos A, Chen Z, Choi H, Ma W, Danciu O Cancers (Basel). 2025; 17(2.

PMID: 39858086 PMC: 11763919. DOI: 10.3390/cancers17020304.

Evaluating the Quality of Real-World Data on Adherence to Oral Endocrine Therapy in Breast Cancer Patients: How Real Is Real-World Data?.

Navarro-Sabate A, Font R, Espinas J, Sola J, Martinez-Soler F, Gil-Gil M Cancers (Basel). 2025; 17(2).

PMID: 39857981 PMC: 11763350. DOI: 10.3390/cancers17020200.

Perspectives of Women with Breast Cancer and Healthcare Providers Participating in an Adherence-Enhancing Program for Adjuvant Endocrine Therapy: A Qualitative Study.

Turcotte V, Guillaumie L, Lemay M, Dionne A, Lemieux J, Labbe A Curr Oncol. 2025; 32(1).

PMID: 39851961 PMC: 11764025. DOI: 10.3390/curroncol32010045.

References

Karve S, Cleves M, Helm M, Hudson T, West D, Martin B . Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009; 25(9):2303-10. DOI: 10.1185/03007990903126833. View

Ejlertsen B, Jensen M, Mouridsen H . Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer. Acta Oncol. 2013; 53(2):174-85. DOI: 10.3109/0284186X.2013.850738. View

Wagner L, Zhao F, Goss P, Chapman J, Shepherd L, Whelan T . Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group.... Breast Cancer Res Treat. 2018; 169(3):537-548. PMC: 6092930. DOI: 10.1007/s10549-018-4713-2. View

Brito C, Portela M, de Vasconcellos M . Adherence to hormone therapy among women with breast cancer. BMC Cancer. 2014; 14:397. PMC: 4057651. DOI: 10.1186/1471-2407-14-397. View

. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-717. DOI: 10.1016/S0140-6736(05)66544-0. View

Condorelli R, Vaz-Luis I . Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther. 2018; 18(11):1101-1112. DOI: 10.1080/14737140.2018.1520096. View

Cramer J, Roy A, Burrell A, Fairchild C, Fuldeore M, Ollendorf D . Medication compliance and persistence: terminology and definitions. Value Health. 2008; 11(1):44-7. DOI: 10.1111/j.1524-4733.2007.00213.x. View

Thurlimann B, Keshaviah A, Coates A, Mouridsen H, Mauriac L, Forbes J . A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005; 353(26):2747-57. DOI: 10.1056/NEJMoa052258. View

Collin L, Cronin-Fenton D, Ahern T, Goodman M, McCullough L, Waller L . Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal Women. Clin Cancer Res. 2020; 27(5):1421-1428. PMC: 7925421. DOI: 10.1158/1078-0432.CCR-20-3974. View

10.

Murphy C, Bartholomew L, Carpentier M, Bluethmann S, Vernon S . Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012; 134(2):459-78. PMC: 3607286. DOI: 10.1007/s10549-012-2114-5. View

11.

Pistilli B, Paci A, Ferreira A, Di Meglio A, Poinsignon V, Bardet A . Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. J Clin Oncol. 2020; 38(24):2762-2772. PMC: 7430219. DOI: 10.1200/JCO.19.01758. View

12.

Franzoi M, Agostinetto E, Perachino M, Del Mastro L, de Azambuja E, Vaz-Luis I . Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 2021; 22(7):e303-e313. DOI: 10.1016/S1470-2045(20)30666-5. View

13.

Gao P, You L, Wu D, Shi A, Miao Q, Rana U . Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement. Patient Prefer Adherence. 2018; 12:887-897. PMC: 5973402. DOI: 10.2147/PPA.S167004. View

14.

Lao C, Lawrenson R, Edwards M, Campbell I . Treatment and survival of Asian women diagnosed with breast cancer in New Zealand. Breast Cancer Res Treat. 2019; 177(2):497-505. DOI: 10.1007/s10549-019-05310-z. View

15.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

16.

Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M . Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018; 103:356-387. DOI: 10.1016/j.ejca.2018.07.005. View

17.

Lee Y, Park Y, Lee J, Lee S, Chung I, Son B . Prescription Refill Gap of Endocrine Treatment from Electronic Medical Records as a Prognostic Factor in Breast Cancer Patients. J Breast Cancer. 2019; 22(1):86-95. PMC: 6438827. DOI: 10.4048/jbc.2019.22.e14. View

18.

Hjorth C, Damkier P, Ejlertsen B, Lash T, Sorensen H, Cronin-Fenton D . Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark. BMC Med. 2021; 19(1):235. PMC: 8482675. DOI: 10.1186/s12916-021-02108-z. View

19.

Garber M, Nau D, Erickson S, Aikens J, Lawrence J . The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care. 2004; 42(7):649-52. DOI: 10.1097/01.mlr.0000129496.05898.02. View

20.

Helland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen V . Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Res. 2017; 19(1):125. PMC: 5706168. DOI: 10.1186/s13058-017-0916-4. View